Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SPRO POWR Grades
- SPRO scores best on the Growth dimension, with a Growth rank ahead of 62.61% of US stocks.
- SPRO's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
- SPRO's current lowest rank is in the Momentum metric (where it is better than 4.63% of US stocks).
SPRO Stock Summary
- For SPRO, its debt to operating expenses ratio is greater than that reported by merely 11.63% of US equities we're observing.
- SPRO's price/sales ratio is 33.37; that's higher than the P/S ratio of 93.16% of US stocks.
- As for revenue growth, note that SPRO's revenue has grown 56.82% over the past 12 months; that beats the revenue growth of 88.46% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Spero Therapeutics Inc are ATNM, GSIT, EIGR, MCRB, and LPTX.
- Visit SPRO's SEC page to see the company's official filings. To visit the company's web site, go to sperotherapeutics.com.
SPRO Valuation Summary
- In comparison to the median Healthcare stock, SPRO's EV/EBIT ratio is 124.91% lower, now standing at -7.3.
- Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
- Over the past 47 months, SPRO's price/sales ratio has gone down 179.1.
Below are key valuation metrics over time for SPRO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SPRO | 2021-08-31 | 33.7 | 6.9 | -8.2 | -7.3 |
| SPRO | 2021-08-30 | 31.6 | 6.4 | -7.7 | -6.8 |
| SPRO | 2021-08-27 | 29.7 | 6.0 | -7.2 | -6.4 |
| SPRO | 2021-08-26 | 29.1 | 5.9 | -7.1 | -6.2 |
| SPRO | 2021-08-25 | 29.6 | 6.0 | -7.2 | -6.4 |
| SPRO | 2021-08-24 | 28.4 | 5.8 | -6.9 | -6.1 |
SPRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SPRO has a Quality Grade of C, ranking ahead of 29.69% of graded US stocks.
- SPRO's asset turnover comes in at 0.128 -- ranking 243rd of 677 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SPRO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.128 | 1 | -1.651 |
| 2021-03-31 | 0.108 | 1 | -1.872 |
| 2020-12-31 | 0.072 | 1 | -2.390 |
| 2020-09-30 | 0.094 | 1 | -2.720 |
| 2020-06-30 | 0.110 | 1 | -2.104 |
| 2020-03-31 | 0.108 | 1 | -1.684 |
SPRO Price Target
For more insight on analysts targets of SPRO, see our SPRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $38.17 | Average Broker Recommendation | 1.42 (Moderate Buy) |
SPRO Stock Price Chart Interactive Chart >
SPRO Price/Volume Stats
| Current price | $19.15 | 52-week high | $23.64 |
| Prev. close | $19.05 | 52-week low | $9.25 |
| Day low | $18.90 | Volume | 411,800 |
| Day high | $19.82 | Avg. volume | 197,273 |
| 50-day MA | $15.57 | Dividend yield | N/A |
| 200-day MA | $16.03 | Market Cap | 615.62M |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest SPRO News From Around the Web
Below are the latest news stories about Spero Therapeutics Inc that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics to Present Data at IDWeek 2021CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will show |
Spero Therapeutics to Present at Three Upcoming Investor ConferencesCAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright |
4 Stocks Insiders Are BuyingWhen insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Computer Task Group The |
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on August 31, 2021, the Compensation Committee of Speros Board of Directors granted non-qualified stock option awards to purchase an aggregate of 98,300 shares of its common stock to 7 new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan. The stock options were granted as inducements material to the new employees becoming employees of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). |
Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out. |
SPRO Price Returns
| 1-mo | 23.87% |
| 3-mo | 34.57% |
| 6-mo | 41.64% |
| 1-year | 89.42% |
| 3-year | 86.83% |
| 5-year | N/A |
| YTD | -1.24% |
| 2020 | 101.66% |
| 2019 | 56.34% |
| 2018 | -47.66% |
| 2017 | N/A |
| 2016 | N/A |
Continue Researching SPRO
Want to do more research on Spero Therapeutics Inc's stock and its price? Try the links below:Spero Therapeutics Inc (SPRO) Stock Price | Nasdaq
Spero Therapeutics Inc (SPRO) Stock Quote, History and News - Yahoo Finance
Spero Therapeutics Inc (SPRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...